Adult patients older than 18 years. Patients admitted to the participating ICUs will be included in this study if the meet eligibility criteria.
Conditions
Brief summary
The primary end point will be survival with a decrease in SOFA score ≥ 3 points at day 7.
Detailed description
- Overall survival in HS critically ill patients, - Temperature, SOFA score and biological (ferritin level, CD25 soluble receptor dosage, fibrinogen level, triglycerides level, hemoglobin level, white blood cells count, platelets count) manifestations related to HS, - To analyse biological inflammatory markers (IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha), - Safety of ruxolitinib in critically ill HS patients
Interventions
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point will be survival with a decrease in SOFA score ≥ 3 points at day 7. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Overall survival in HS critically ill patients, - Temperature, SOFA score and biological (ferritin level, CD25 soluble receptor dosage, fibrinogen level, triglycerides level, hemoglobin level, white blood cells count, platelets count) manifestations related to HS, - To analyse biological inflammatory markers (IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha), - Safety of ruxolitinib in critically ill HS patients | — |
Countries
France
Outcome results
None listed